Retsef Levi Explains His Vote against Routine RSV Monoclonal Use in Newborns
Levi is no stranger to weighing risk. A professor at MIT with deep experience in data analytics and risk-based decision-making, he had combed through five clinical trials of RSV monoclonals, including clesrovimab and its predecessor, nirsevimab.
Retsef Levi Explains His Vote against Routine RSV Monoclonal Use in Newborns Read Journal Article











